Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.

doi:10.1158/1078-0432.CCR-20-4607

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2021

Chua Khi Pin, Teng Yvonne H F, Tan Aaron C, Takano Angela, Alvarez Jacob J S, Nahar Rahul, Rohatgi Neha, Lai Gillianne G Y, Aung Zaw Win, Yeong Joe P S, Lim Kiat Hon, Naeini Marjan Mojtabavi, Kassam Irfahan, Jain Amit, Tan Wan Ling, Gogna Apoorva, Too Chow Wei, Kanesvaran Ravindran, Ng Quan Sing, Ang Mei Kim, Rajasekaran Tanujaa, Anantham Devanand, Phua Ghee Chee, Tan Bien Soo, Lee Yin Yeng, Wang Lanying, Teo Audrey S M, Khng Alexis Jiaying, Lim Ming Jie, Suteja Lisda, Toh Chee Keong, Lim Wan-Teck, Iyer N Gopalakrishna, Tam Wai Leong, Tan Eng-Huat, Zhai Weiwei, Hillmer Axel M, Skanderup Anders J, Tan Daniel S W

Abstract excerpt

PURPOSE: Despite the established role of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC, drug resistance inevitably ensues, with a paucity of treatment options especially in EGFR T790M-negative resistance. EXPERIMENTAL DESIGN: We performed whole-exome and transcriptome analysis of 59 patients with first- and second-generation EGFR TKI-resistant metastatic EGFR-mutated NSCLC to characterize and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Carcinoma, Non-Small-Cell Lung

Share to Colorectal Cancer Treatments and Studies

Share to ErbB Receptors

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 34261696
DOI: 10.1158/1078-0432.CCR-20-4607
PMCID: PMC9401458

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.PMID 34261696Read ↗

Dissecting the immune evasion and therapeutic resistance mechanisms in EGFR/TP53 co-mutated non-small cell lung cancer: implications for targeted and immunotherapy strategies.Semantic proximity Read ↗

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic SequencingSemantic proximity Read ↗

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19Del and L858R Mutation SubtypesSemantic proximity Read ↗

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.Semantic proximity Read ↗

Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticitySemantic proximity Read ↗

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity Read ↗

Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer.Semantic proximity Read ↗

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancerSemantic proximity Read ↗

Longitudinal spatial multi-omics delineates tumor microenvironment remodeling across sequential EGFR-TKIs in EGFR-mutant NSCLCSemantic proximity Read ↗

Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.Semantic proximity Read ↗

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.Semantic proximity Read ↗

AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.